GFF and Sage Bionetworks Collaborate on an NF1 Research Tools Database
The Gilbert Family Foundation (GFF) is excited to announce the development of a database for neurofibromatosis type 1 (NF1) research tools in collaboration with Sage Bionetworks. The database aims to support the development of a robust NF1 research toolkit while also lowering the barrier of entry to research for new-to-NF1 investigators. GFF and Sage intend the database to be used by a variety of stakeholders in the NF1 research community, including researchers, drug developers, and research funders.
Gilbert Family Foundation, Rocket Community Fund Announce $500 Million Philanthropic Investment in Detroit, First Allocation Will Pay Off Property Tax Debt of 20,000 Low-Income Detroit Homeowners
DETROIT, March 25, 2021 – The Gilbert Family Foundation (GFF) and Rocket Community Fund today announced an unprecedented and transformational $500 million philanthropic investment over the next ten years, to be accomplished through strategic contributions to community organizations that will build economic opportunity in Detroit neighborhoods. The Gilbert Family Foundation will contribute $350 million, and […]
Seeking a True Cure: Developing Gene Replacement and Editing Therapies to Address the Cause of NF1
GFF's Gene Therapy Initiative seeks to explore and develop gene-targeting therapeutic strategies for neurofibromatosis type 1 (NF1) that address the underlying cause of the disease. Targeting the mutated gene itself could yield a more effective, comprehensive response for a greater range of patients.
GFF’s Vision Restoration Initiative: Exploring Regenerative Therapies
Optic pathway gliomas (OPGs) are slow-growing brain tumors that arise in or around the optic nerve and can cause the degeneration of the optic nerve and retinal ganglion cells (RGCs) leading to vision loss. GFF's Vision Restoration Initiative aims to develop new therapies to protect and restore vision for patients affected by OPGs, including methods that address severe vision loss by regenerating RGCs and the optic nerve.
GFF’s Vision Restoration Initiative: Exploring Neuroprotection/Neuroenhancement Therapies
Approximately 1 in 5 patients with neurofibromatosis type 1 (NF1) develop optic pathway gliomas (OPGs). These tumors can cause degeneration of the optic nerve and retinal ganglion cells (RGCs), ultimately leading to vision loss. GFF's Vision Restoration Initiative aims to develop neuroprotection/neuroenhancement therapies that protect and increase performance of injured RGCs and the optic nerve to improve visual function.